[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autistic-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autistic-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,90,122,147,176,200],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100587940","early-phase-1-prednisone-in-adults-with-an-immune-mediated-subtype-of-autism-spectrum-disorder-100587940",false,"NCT06934915","Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder","Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups Trial of Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder","PREDICT","Inclusion Criteria:\n\n1. 18 to 50 years of age (inclusive) and assigned male at birth.\n2. Diagnostic Statistical Manual of Mental Disorders (DSM), Fourth Edition, Text Revision (DSM-IV-TR) diagnosed autistic disorder, and DSM, Fifth Edition, Text Revision (DSM-5-TR) diagnosed autism spectrum disorder (ASD), level 2 or 3. A qualified (board-eligible or board-certified) psychiatrist or psychologist, with experience in diagnostic determinations of ASD, will make a final diagnostic determination based on clinical history, clinical observations, medical records, mental status exams, and screening measures.\n3. A Clinical Global Impression-Severity (CGI-S) rating ≥ 4 (\"Moderate\") at screening (and baseline).\n4. A non-verbal IQ in the range of moderate intellectual disability or higher (≥ 35), as measured by the non-verbal Abbreviated IQ (ABIQ) score of the Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), or mental age of at least 18 months, as measured by the Cognitive and Adaptive Behavior subscales of the Developmental Profile (DP-4) Parent\u002FCaregiver Interview form.\n5. Participation of a study partner who has consistent contact with the participant and is willing and able to attend visits, oversee the participant's compliance with the protocol and study medication, and report on the participant's status through study assessments.\n6. Participant reports ≥ 1 of the following:\n\n   * A diagnosed comorbid autoimmune disease (e.g., Crohn's disease, Graves' disease, Hashimoto's disease, psoriasis, rheumatoid arthritis, ulcerative colitis, type 1 diabetes mellitus, etc.).\n   * Current biomarker evidence of critical indicators of inflammation\u002Fautoimmunity, such as elevated levels of C-reactive protein (CRP) or abnormal value of antinuclear antibodies (ANA).\n   * A significant family history of autoimmunity, defined as having ≥ 1 first-degree relative or ≥ 2 second-degree relatives with autoimmune diseases. The Principal Investigator (PI) will make the final determination on this criterion.\n7. Any concomitant medications or interventions for ASD-related symptoms (e.g., alpha-2 agonists, anticonvulsants, antidepressants, antipsychotics, anxiolytics, gastrointestinal medications, medications for sleep disorders, probiotics, stimulants, behavioral therapies, psychosocial interventions, speech therapy, etc.) have been stable for at least 4 weeks prior to the screening visit and the participant\u002Fstudy partner intend to maintain a stable regimen throughout the trial.\n8. Participant can tolerate swallowing large capsules.\n9. Participant is willing and able, in the investigator's opinion, to comply with all study procedures.\n\nIndividuals must satisfy the following criteria to be enrolled as study partners:\n\n1. The study partner is fluent in English.\n2. The study partner is a caregiver or an individual who has consistent contact with the participant, knows the participant well, and is willing and able to attend visits, oversee the participant's compliance with the protocol and study medication, and report on the participant's status through study assessments. The PI will make the final determination on this criterion.\n\nExclusion Criteria:\n\n1. DSM-5-TR diagnosed ASD, level 1, or presence of another DSM-IV-TR diagnosed pervasive developmental disorder, such as Asperger's disorder, childhood disintegrative disorder, Rett syndrome, or pervasive developmental disorder not otherwise specified (PDD-NOS). A qualified psychiatrist or psychologist will make a diagnostic determination after reviewing clinical history, clinical observations, medical records, mental status exams, and screening measures.\n2. A CGI-S rating \\\u003C 4 at screening (or baseline).\n3. A non-verbal IQ in the range of severe or profound intellectual disability (\\\u003C 35), as measured by the non-verbal ABIQ score of the SB-5, or mental age below 18 months, as measured by the Cognitive and Adaptive Behavior subscales of the DP-4 Parent\u002FCaregiver Interview form. Individuals testing below 18 months may be enrolled after a case review by the PI and study psychologist, especially if testing scores were likely underestimated due to uncooperative behavior.\n4. Previous documentation of a prolonged electroencephalogram (EEG) suggestive of Landau-Kleffner syndrome or continuous spike and wave during sleep (CSWS) syndrome.\n5. Presence of a defined genetic disorder, such as Angelman syndrome, Fragile X syndrome, Noonan syndrome, Tuberous sclerosis, Williams syndrome, or any documented chromosomal or genetic abnormality with proven clinical significance in the etiology of ASD.\n6. Documented significant pre- or post-natal central nervous system insult, such as an in-utero cerebral vascular accident, that is believed to have significantly contributed to the development of the individual's ASD.\n7. Mitochondrial disorder verified by skin and\u002For muscle biopsy.\n8. History of bipolar disorder or psychotic disorder, including major depressive disorder with psychotic features, schizoaffective disorder, or schizophrenia. History of a significant and interfering comorbid major psychiatric disorder, including obsessive-compulsive disorder, post-traumatic stress disorder, or substance use disorder requiring \\> 1 psychiatric hospitalization for treatment of specific comorbid psychiatric disorders above and beyond target symptoms associated with ASD, such as aggression, irritability, self-injury, property destruction, mood swings, or severe tantrums. Minor psychiatric disorders, such as adjustment disorder, attention-deficit hyperactivity disorder, generalized anxiety disorder, major depressive disorder, persistent depressive disorder, or social anxiety disorder, may not exclude participation. The PI will make the final determination on this exclusion criterion.\n9. Concomitant medications or interventions for ASD-related symptoms (e.g., alpha-2 agonists, anticonvulsants, antidepressants, antipsychotics, anxiolytics, gastrointestinal medications, medications for sleep disorders, probiotics, stimulants, behavioral therapies, psychosocial interventions, speech therapy, etc.) have not been stable for at least 4 weeks prior to the screening visit.\n10. An active bacterial, fungal, helminthic, protozoan, or viral infection that could be exacerbated by a course of prednisone, as determined by the PI.\n11. Significant medical findings from history, physical examination, or laboratory testing that may be incompatible with prednisone use (e.g., participants with chronic infectious conditions or unstable diabetes mellitus).\n12. Individuals with a history of seizures being treated with an anticonvulsant may be eligible if seizure-free for at least 6 months and the anticonvulsant dose has been stable for at least 4 weeks prior to the screening visit.\n13. Use of immunosuppressive agents within the 6 months prior to the screening visit or concurrent use of immunosuppressive agents that, in the judgment of the PI, would interfere with study outcomes or pose unreasonable risk with prednisone administration.\n14. A known hypersensitivity to prednisone or any other component of the study product.\n15. The participant is deemed unsuitable for any reason by the PI, including an inability to complete or comply with study requirements.\n\nIndividuals may be excluded from enrollment as study partners if either of the following criteria are met:\n\n1. The study partner is not fluent in English.\n2. The study partner is deemed unsuitable for any reason by the PI, including an inability to complete or comply with study requirements.","MALE","18 Years","50 Years",{"count":21,"type":22},32,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The goal of this clinical trial is to learn how prednisone affects adults with autism spectrum disorder (ASD). It will also learn about the safety of prednisone. The main questions it aims to answer are:\n\n* How does prednisone affect the core features and associated target symptoms of ASD in adults with an immune-mediated subtype of ASD?\n* Is prednisone safe for autistic adults without causing too many side effects?\n* Does this study warrant larger trials studying anti-inflammatory drugs in this subject population?\n\nResearchers will compare the drug prednisone to a placebo (a look-alike substance that contains no drug) to see how prednisone affects autistic adult males.\n\nParticipants will:\n\n* Visit the clinic 2 times for a screening and baseline visit.\n* Take prednisone or a placebo every day for 16 weeks.\n* Visit the clinic 2 times for checkups, tests, questionnaires, and dose changes, and 1 time for a follow-up visit 4 weeks after stopping the study drug.\n* Provide blood and urine samples for testing up to 4 times.\n* Complete 8 remote calls every 1-2 weeks for checkups and dose changes.\n* Keep a diary of the dose and times they take the study drug every day and any symptoms or side effects they experience.",[28,29,30,31],"Autism Spectrum Disorder","Autism Spectrum Disorders","Autistic Disorder","Autism",[28,30,31,33,34,35,36,37,38,39,40],"Autoimmunity","Autoimmune Disorders","Inflammation","Neuroinflammation","Anti-Inflammatory Agents","Corticosteroids","Glucocorticoids","Prednisone","NOT_YET_RECRUITING","2026-05-08",{"date":44,"type":45},"2026-05-12","ACTUAL",{"date":47,"type":22},"2026-11",{"date":49,"type":22},"2029-02",{"name":51,"class":52},"Christopher John McDougle, M.D.","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":53},"100533589","alpha-auditory-entrainment-for-cognitive-enhancement-and-sensory-hypersensitivity-in-youth-with-developmental-disorders-100533589","NCT06227780","Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders","FX ENTRAIN: Perturbation of Neurodynamics Underlying Sensory Hyperarousal and Statistical Learning in Youth With FXS","ENTRAIN","Inclusion Criteria:\n\n* FXS Cohort: 1) Aged 5-10 years, inclusive; 2) Patient has full FMR1 mutation confirmed by genetic testing.\n* ASD Cohort: 1) Aged 5-10 years, inclusive; 2) Have no known genetic mutation; 3) Have documentation of ASD diagnosis; 4) Score ≤ 15 on SCQ screen; 5) Be in good health per investigator.\n* TDC Cohort: 1) Aged 5-10 years, inclusive; 2) Have no known genetic mutation; 3) Have documentation of ASD diagnosis; 4) Score ≤ 15 on SCQ screen; 5) Be in good health per investigator; 6) Patient has met normal developmental milestones; Patient has no family history of heritable neuropsychiatric disorders; 7) Patient has an IQ greater than 85 on the Stanford-Binet; 8) Score ≤8 on an SCQ screen.\n\nExclusion Criteria:\n\n* All subjects: 1) Patient has auditory or visual impairments that cannot be corrected; 2) History of substance abuse or dependence within the past 6 months",true,"ALL","5 Years","10 Years",{"count":67,"type":22},180,[69],"NA","Fragile X Syndrome (FXS) is a complex neurodevelopmental disorder caused by a mutation on the X chromosome. Scientists have investigated FXS extensively in both humans and animals. Thus far, phenotypic rescue in animal models has not resulted in treatment breakthroughs in humans, though some important discoveries have been made. Research has shown that individuals with FXS process sounds differently than those in the typical population, and they also show baseline differences in brain activity, including high gamma activity, increased theta activity, and decreased alpha activity. The investigators' central hypothesis is that these alterations in brain activity (specifically alpha and gamma activity) impair the brain's ability to process new information, thereby impeding cognitive functioning and increasing sensory sensitivity. The investigators propose that auditory entrainment, a technique that involves playing special sounds through headphones, will normalize brain activity in individuals with FXS and lead to increased cognitive function and decreased sensory hypersensitivity.",[72,28,30,73],"Fragile X Syndrome","Asperger Syndrome",[75,30,28,72,76,77,78,79,31],"Neurodevelopmental Disorders","Fragile X","FXS","ASD","Asperger","RECRUITING","2026-03-25",{"date":83,"type":45},"2026-03-30",{"date":85,"type":45},"2023-05-24",{"date":87,"type":22},"2028-05-24",{"name":89,"class":52},"Children's Hospital Medical Center, Cincinnati",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":63,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":109,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":53},"100452845","telehealth-parent-implemented-intervention-for-young-children-with-autism-spectrum-disorder-asd-100452845","NCT05176808","Telehealth Parent-Implemented Intervention for Young Children With Autism Spectrum Disorder (ASD)","Telehealth Parent-Implemented Intervention to Improve Social- Communication Outcomes in Young Children With ASD","Inclusion Criteria:\n\n* Meeting study criteria for ASD based on:\n\n  * Autism Diagnostic Observation Schedule(ADOS) criteria for mild-to- moderate concern or greater (for children between 18 and 30 months) or algorithm cut-offs for ASD or autism (31-33 months),\n  * Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)( criteria for ASD)\n  * ASD diagnosis by clinician (clinical best estimate) by study team clinical research experts\n* Meeting study criteria for social communication delay based on:\n\n  * Scoring a T score of \\\u003C35 on Expressive Language and\u002For Receptive Language subscales, Nonverbal developmental quotient of \\> 50 (Visual Reception and Fine Motor subscales averaged) AND Visual reception \\> 12 months\n* Nonverbal developmental quotient (DQ) of \\> 63 based on the Visual Reception and Fine Motor subscales\n* Gestational age of 36-42 weeks;\n* Birth weight of \\> 2,500 grams;\n* Absence of identifiable neurological (e.g., epilepsy), genetic (e.g., Down syndrome, fragile X, tuberose sclerosis, neurofibromatosis) or severe sensory- motor (e.g., cerebral palsy) conditions.\n* Able to walk independently.\n* Children must produce at least three different types of intentional directed (with eye contact or pairing vocalization and gesture) nonverbal or verbal communicative acts per day, with clear and specific examples, per parent report in the Eligibility Interview.\n\nExclusion Criteria:\n\n* Having a primary language other than English\n* Family lives \\>40 miles from a Kennedy Krieger Institute-Center for Autism Services, Sciences, and Innovation (CASSI) site.\n* Child lives in foster care.","18 Months","42 Months",{"count":100,"type":22},188,[69],"The primary objective of this research study is to improve outcomes involving core social-communication symptoms for young children with ASD or social communication delays by increasing access to clinically validated early behavioral intervention through a telehealth parent coaching model. The investigators will test the hypothesis that telehealth-delivered Naturalistic Developmental Behavioral Intervention parent coaching (TC) is non-inferior to in-person coaching (IPC) for the treatment of core social-communication symptoms in toddlers with either a social communication delay or ASD.",[28,30,104,31,73,105,106,107,108],"Active Autistic Disorder","PDD-NOS","Social Communication Delay","Mixed Expressive Receptive Language Disorder","Other Symbolic Dysfunctions",[110,111,112],"Social Communication","Language","Engagement","2026-03-20",{"date":115,"type":45},"2026-03-24",{"date":117,"type":45},"2022-02-07",{"date":119,"type":22},"2026-12-01",{"name":121,"class":52},"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":63,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":53},"100582177","randomized-clinical-trial-of-tune-in-30-a-socialemotional-program-for-adults-with-autism-spectrum-disorder-100582177","NCT06859918","Randomized Clinical Trial of TUNE In 3.0: A Social\u002FEmotional Program for Adults With Autism Spectrum Disorder","ASPE Subproject - Training to Understand and Navigate Emotions and Interactions (TUNE In)","Inclusion Criteria:\n\n* 18 years of age or older\n* Meet ASD diagnostic criteria supported by an outside diagnostic evaluation and\u002For by the clinical and developmental information gathered from a phone screen\n* Be willing to complete screening surveys (outcome measures)\n* Social Responsiveness Score, Second Edition, self-report SRS survey score of greater than or equal to 60\n\nExclusion Criteria:\n\n* Severe self-injurious or aggressive behaviors; or with suicidal or homicidal ideation or behaviors (e.g. suicide attempt) within the last 6 months\n* Major mood episode (major depressive episode, manic episode), psychotic symptoms, or a psychiatric hospitalization within the last 6 months\n* A history of intellectual disability or low Shipley-2 score",{"count":130,"type":22},40,[69],"The purpose of this study is to test a novel, cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder.\n\nThe treatment, named TUNE In (Training to Understand and Navigate Emotions and Interactions), includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.\n\nThe Investigators will test the efficacy of TUNE In to improve social functioning in adults with autism spectrum disorder (ASD), using a randomized controlled trial using the SRS-2 as the primary outcome measure.",[28,31,30,73],[135,136,137],"Social Skills","Emotion Regulation","Autistic Adults","2026-03-11",{"date":140,"type":45},"2026-03-13",{"date":142,"type":45},"2025-03-24",{"date":144,"type":22},"2027-12",{"name":146,"class":52},"University of Pennsylvania",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":62,"sex":63,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":157,"studyType":158,"phases":4,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":53},"100222106","proteomic-biomarker-tests-in-blood-samples-from-children-with-autism-spectrum-disorder-asd-100222106","NCT02168868","Proteomic Biomarker Tests in Blood Samples from Children with Autism Spectrum Disorder (ASD)","Inclusion Criteria:\n\n1. Male and female children\n2. Child aged 2-12 years with diagnosed ASD according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00) OR Child aged 2-18 years diagnosed ASD according to DSM-IV (299.00) or DSM-V (299.00) AND scheduled to undergo stem cell transplantation OR Child aged 10-19 months not diagnosed with ASD but with a sibling diagnosed with ASD according to (DSM)-IV (299.00) or DSM-V (299.00) (herein termed \"high-risk infants\") OR Mothers of recruited high-risk infants OR A typically developing child aged 2-12 years with no signs of ASD or history of ASD in the immediate family\n3. Informed consent signed by the parent\u002Flegal guardian\n\nExclusion Criteria:\n\n1. Child and\u002For mother completed treatment with systemic steroids or immune suppressants less than 4 weeks before the screening visit\n2. Child and\u002For mother diagnosed with severe infectious diseases or sepsis over the last 6 months\n3. Child with ASD treated for a severe convulsive disorder (intractable seizures)\n4. Child and\u002For mother with hematological or malignant disorder\n5. For children in the SCT cohort: No new planned immune-modulating treatment (other than SCT) for at least 6 months before or after planned stem cell transplantation date\n6. If the PI suspects that the participant will not comply with study requirements, the participant may be excluded.","10 Months","19 Years",{"count":156,"type":22},900,"1 Day","OBSERVATIONAL","Behavioral testing is the gold standard for diagnosing autism spectrum disorder (ASD). These tests, including ADOS and ADI-R, are subjective, require trained staff to administer, are time-consuming, and can only be administered at a later age. Blood-, urine- or stool-based diagnostic biomarker test for ASD would enable objective early diagnosis, potentially even before clinical symptoms are present, eliminate the need for trained staff and enable early intervention. Such a test would not only conserve money and time but would also provide clues to ASD pathogenesis.\n\nTo date, no definitive treatment exists for ASD. Most therapies are symptom-focused, generally focusing on behavioral, social and communication skills. Recent works have reported on promising outcomes of mesenchymal stem cell (MSC) treatment of children with ASD. MSCs are multipotent, non-hematopoietic, easily isolatable and expandable stem cells involved in tissue repair, immunomodulatory responses and neuromodulation. MSC treatment of children with ASD has reportedly led to improvements in speech, sociability, eye coordination, balance, cognition and overall well-being. At the base of this approach lies the known plasticity of the human brain and immune system in the early childhood years and the ability of MSCs to modulate atypical inflammatory and immune activities. Assessment of ASD biomarker profiles in children with ASD who have undergone one or more SCT sessions may shed light on the mechanism of action, assist in better defining ASD-specific diagnostic markers and monitor treatment outcomes.",[30],[162,163,35,164,165,31,30],"Autoimmune Diseases","Child Development Disorders","Risk Factors","Pervasive","2024-11-21",{"date":168,"type":45},"2024-11-25",{"date":170,"type":45},"2013-05",{"date":172,"type":22},"2030-12",{"name":174,"class":175},"Benjamin Gesundheit","INDUSTRY",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":62,"sex":63,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":53},"100539847","compass-across-settings-cast-for-improving-transition-outcomes-for-students-with-asd-100539847","NCT06309160","COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD","COMPASS Across Settings (CAST) for Integrating School, Home, and Community Services and Improving Transition Outcomes for Students With ASD","CAST","Inclusion Criteria:\n\n* Students with verified autism and IEPs that designate services for autism\n* Caregivers of students with autism\n* Special education teachers of students with autism\n* Pre-employment specialists of students with autism\n\nExclusion Criteria:\n\n* Not planning to move or leave their job over the school year","16 Years","99 Years",{"count":187,"type":22},297,[69],"Purpose: The purpose of this project is to develop and test the COMPASS \\[Collaborative Model for Competence and Success\\] Across Settings (CAST) intervention to enhance the goal setting and attainment skills of autistic youth. Despite federal education law mandating transition services as part of the Individualized Education Program (IEP) for ensuring good outcomes for students with disabilities, current educational practices have been unable to demonstrate that autistic students experience positive postsecondary outcomes. There are existing, evidence-based interventions aimed at supporting positive outcomes for these students. However, these interventions have not systematically provided coaching support to the caregivers, students, and employment specialists. To address these issues, CAST will integrate three evidence-based interventions for supporting student transitions while providing this critical coaching support. By doing so, CAST aims to align the priorities and goals of interventions across home, school, and community settings to better support positive postsecondary outcomes for autistic students.",[31,28,30],"2024-03-06",{"date":193,"type":45},"2024-03-13",{"date":195,"type":45},"2023-12-01",{"date":197,"type":22},"2027-07",{"name":199,"class":52},"Ball State University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":63,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":212,"conditions":213,"keywords":219,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":241},"100302839","squed-series-281-home-use-and-treatment-of-autowave-reverberator-of-autism-100302839","NCT03222375","SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism","The Home-Use of Semiconducting QUantum Excitonic Device: Image Converter\u002FSound Converter\u002FElectromagnetic Converter to Improve Communicative Efforts, Speech, Language and Related Cognitive Functions in Children With Autism","SQUED™","Inclusion Criteria:\n\n* Clinical diagnosis of autism or related conditions.\n* History of Late complications at Natal Trauma:\n\n  1. Cerebral level of Natal Trauma - brain injury;\n  2. Cervical level of Natal Trauma - injury of vertebral;\n  3. Cerebral anoxia.\n* Identified language deficit(s) and\u002For other cognitive or behavioral impairments (which will be specific to each sub-study).\n* Adequate ability to perform the research tasks set for the Age level:\n\n  1. Infant - greater than 1 month to 2 years of age;\n  2. Child - greater than 2 to 12 years of age;\n  3. Adolescent - greater than 12 through 21 years of age.\n* Presence on the Skin of the interruption of Autowave front (interruption of hair separatrix - dorsal\u002Fventral) and\u002For of the Autowave Reverberators:\n\n  1. Photo of Spiral Autowaves, generated by the kernel of Autowave Reverberator - the kernel having an excitation \"tongue\";\n  2. Graphics on tracing paper of Spiral Autowaves, generated by the kernel of Autowave Reverberator - the kernel having an excitation \"tongue\".\n* Presence of Clinical protocol CRF-SQUED™:\n\n  1. Diagnostics of Autowave reverberators and Nonlinear Control of Autowave reverberators in Active media (Autowave interaction of patient - Algorithmic approach);\n  2. Mathematical Modeling of Autowave Reverberator and Computational Simulation of the treatment code (Trade Secret), and creation Active medium SQUED™ for a patient;\n  3. Recording for a patient of treatment code (Trade Secret) - Autowave regime: Hysteresis of Spiral Autowaves; Drift of Spiral Autowaves; Annihilation of Autowave reverberator.\n* Magnetogram of region of Home-use and Geographic coordinates of Home-use.\n\nExclusion Criteria:\n\n* Peripheral blindness - precludes use of Image converter SQUED™ (iSQUED™).\n* Peripheral deafness - precludes use of Sound converter SQUED™ (sSQUED™).\n* Any implanted metal device - precludes use of Electromagnetic converter SQUED™ (eSQUED™).\n* Any implanted cardiac pacemaker - precludes use of Electromagnetic converter SQUED™ (eSQUED™).","1 Month","21 Years",{"count":211,"type":22},80,"Locomotor, transport and information functions in human body systems are carried out by active media in autowave regimes! Any living organism is a (micro-macro-mega) hierarchy of autowave subsystems-an ensemble of loosely coupled subsystems of a simpler structure. From the highest levels of the hierarchy, Autowave Codes-Signals arrive, which determine the transitions of subsystems from one autowave regime to another Autowave interaction (of Complex Coherent Action). Autowave interaction is a process associated with the evolution and interaction of spatial and wave structures in the active media of the organism.\n\nChaos in organism functioning tells about health. Periodicity - Autowave reverberator may presage a disease - Autism Spectrum Disorder; Chaotic nature of oscillations in active media of physiological systems is more optimal for their vital functions than periodic one. Firstly, systems that function in chaotic regimes, can re-arrange themselves faster and easier in case of change of environmental conditions, i.e. the so called adaptive control is more easily implemented in them. Secondly, \"spreading\" of oscillations strength along comparatively wide frequency band takes place in chaotic regime.\n\nWhen an organism is young and healthy, physiological systems show the elements of chaotic behavior, i.e. irregularity and chaotic dynamics are the extremely important characteristics of health. Decrease in changeability and appearance of stable periodicity of Autowave reverberator are often connected with Autism.\n\nThe main purpose is to study brain plasticity (the changes that occur in the brain through Autowave reverberator) in children with autism. Research suggests that during development, the brains of children may change in response to their Autowave reverberator differently than the brains of typically developing individuals. Investigators want to understand why and how this difference may contribute to the symptoms of autism spectrum disorder (ASD). In this study, the investigators will be examining the effects of non-invasive neuromodulation SQUED™ series 28.1 home-use for Treatment of Autowave reverberator of Autism.\n\nIntegrative Team World Organization of Medical Synergetics (WOMS) - collaborations between physicians and researchers with expertise in biostatistics, physics, mathematics, engineering, and computer science.",[30,28,214,75,215,216,217,218],"Child Development Disorders, Pervasive","Mental Disorders","Asperger's Syndrome","Neurobehavioral Manifestations","Nervous System Diseases",[220,221,222,223,224,225,226,227,228,229,230,231,232],"Yaroshuk's MEGA-DISCOVERY · DIAGNOSTICS · TREATMENT","Yaroshuk's Scientific Medical School","Center of Synergetics","Controlling spatiotemporal chaos\u002FDr. Synergetic","Autowave processes in Medicine","Autowave Reverberator","Bifurcation of Dynamic systems on a plane","Spiral Autowaves","Drift of Spiral Autowaves","Excitable medium and Cellular Automata","Stochastic Resonance and Coherence Resonance","Autowaves\u002FSQUED","Theory of Semiconducting QUantum Excitonic Device","2017-11-24",{"date":235,"type":45},"2017-11-28",{"date":237,"type":45},"2017-09-26",{"date":144,"type":22},{"name":240,"class":52},"American Federation of Medical Synergetics",2]